The solutions will combine human milk oligosaccharides (HMOs) from dsm-firmenich and probiotics from Lallemand Health Solutions with the aim to make the composition of infant formula closer to breast milk.
Lallemand Health Solutions (Heerlen, Netherlands) and dsm-firmenich (Kaiseraugst, Switzerland) have announced a new partnership to launch synergistic synbiotic solutions to support early life nutrition. The solutions will combine human milk oligosaccharides (HMOs) from dsm-firmenich and probiotics from Lallemand Health Solutions with the aim to make the composition of infant formula closer to breast milk, and therefore support the establishment of a microbiome that closely resembles that of a breast-fed infant. This helps support bottle-fed infants’ immune health, gut microbiome, and development.
"All infants deserve the best start in life, and access to optimum nutrition during early life is essential. Our partnership with Lallemand Health Solutions marks a significant milestone in the early life nutrition market with the development of game-changing synbiotic solutions that aim to narrow the gap in outcomes between breastfed and non-breastfed infants when breastfeeding is not possible," says James Young, vice president of early life nutrition at dsm-firmenich, in a press release. "By leveraging our deep understanding of HMOs and Lallemand Health Solution's world-class probiotics, we are poised to set a new standard for synbiotics in infant nutrition. We are confident this collaboration will enable us to meet the evolving needs of parents and infants, ultimately making a positive impact on the lives of families globally."
"At Lallemand Health Solutions, we are committed to pushing the boundaries of probiotic research and development to create solutions that promote optimal health and well-being," adds Isabelle Champié, vice-president of sales and marketing at Lallemand Health Solutions. "Our Expert’Biotic probiotic baby strains have been clinically documented on more than 1,600 infants, with proven safety and efficacy. By combining them with dsm-firmenich’s science-backed HMOs, we have created innovative, synergistic solutions that establish a strong foundation for infants’ health by supporting the development of their microbiome during the critical early life period.”
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.